TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05239728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet
Study: NCT05838066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 mg/kg loading dose followed by 6 mg/kg per cycle, D1 Q3W, IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m\^2, D1 Q3W, IV infusion
Study: NCT04547946

Intervention type: DRUG
Intervention: dabrafenib + trametinib
Description: There was no treatment allocation. Patients administered adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib (Mekinist®) by prescription that had started before inclusion of the patient into the study could be enrolled.
Study: NCT05970562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulatory Voice Monitoring with Biofeedback (AVM-B)
Description: AVM-B is software on the Voice Health Monitor that uses a neck-placed accelerometer to sense neck skin vibrations during voicing in daily life. The AVM-B consists of cues every time the patient exceeds a subject-specific threshold, \[100% frequency AVM-B\] and/or summary statistics every 2 minutes of voicing \[Summary AVM-B\].

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conversation Training Therapy
Description: CTT is a 4-week (1 45-minute session per week) evidence-based voice therapy for patients with VH, developed primarily to maximize the amount and speed of generalization outside the therapy session. It consists of 3 required targets: Decreased overall auditory-perceptual voice severity, improved discrimination between baseline and improved voicing, and adherence to CTT recommendations in daily life. The three optional targets are decreased overall auditory-perceptual severity across an increased pitch range, loudness range, and decreased rate of speech. All voice-related targets are modified through practicing voicing with increased forward resonance and mean airflow in spontaneous speech/conversation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation Training Therapy
Description: CTT is a 4-week (1 45-minute session per week) evidence-based voice therapy for patients with VH, developed primarily to maximize the amount and speed of generalization outside the therapy session. It consists of 3 required targets: Decreased overall auditory-perceptual voice severity, improved discrimination between baseline and improved voicing, and adherence to CTT recommendations in daily life. The three optional targets are decreased overall auditory-perceptual severity across an increased pitch range, loudness range, and decreased rate of speech. All voice-related targets are modified through practicing voicing with increased forward resonance and mean airflow in spontaneous speech/conversation.
Study: NCT05513443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation, IRE
Description: IRE involves the use of high voltage electrical pulses to treat solid tumors by increasing membrane permeability and inducing membrane disruption, leading to cell death. The technique is used in Sweden today in radical ablative therapies in the treatment of tumors in the liver, kidney and pancreas. Prior to treatment a Foley catheter is placed. During the treatment, which takes place under anesthesia, the patient is placed in gynecological position and the tumour lesion is located with BK transrectal fusion ultrasound. Thereafter the needles are placed transperineal around the tumor in the prostate using a brachytherapy grid (17Ga Civco brachytherapy grid), guided by the ultrasound/MRI fusion images. Through the needles electrical pulses are then sent to treat the tumor in the center using the Nanoknife technique. After treatment patients are treated with diuretics to flush the kidneys post treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation, IRE
Description: IRE involves the use of high voltage electrical pulses to treat solid tumors by increasing membrane permeability and inducing membrane disruption, leading to cell death. The technique is used in Sweden today in radical ablative therapies in the treatment of tumors in the liver, kidney and pancreas. Prior to treatment a Foley catheter is placed. During the treatment, which takes place under anesthesia, the patient is placed in gynecological position and the tumour lesion is located with BK transrectal fusion ultrasound. Thereafter the needles are placed transperineal around the tumor in the prostate using a brachytherapy grid (17Ga Civco brachytherapy grid), guided by the ultrasound/MRI fusion images. Through the needles electrical pulses are then sent to treat the tumor in the center using the Nanoknife technique. After treatment patients are treated with diuretics to flush the kidneys post treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical prostatectomy
Description: Radical prostatectomy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Radiation therapy for prostate cancer
Study: NCT05832931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLS240
Description: Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-Label Extension PLS240
Description: Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
Study: NCT06290141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riliprubart
Description: Pharmaceutical form:Solution-Route of administration:IV solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Solution-Route of administration:IV solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riliprubart
Description: Pharmaceutical form:Solution-Route of administration:SC solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riliprubart
Description: Pharmaceutical form:Solution-Route of administration:SC solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Solution-Route of administration:SC solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIg
Description: Pharmaceutical form:Concentrate for solution for infusion (or any other formulation approved locally)-Route of administration:IV solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Placebo to match intravenous immunoglobulin IVIg for IV infusion-Route of administration:IV solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIg premedication
Description: Pharmaceutical form:Per respective labels-Route of administration:Per respective labels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIg premedication
Description: Pharmaceutical form:Per respective labels-Route of administration:Per respective labels
Study: NCT04777331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasinezumab
Description: Prasinezumab will be administered as an IV infusion to participants Q4W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prasinezumab placebo will be administered to participants.
Study: NCT06508827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron dextran 1000 mg IV
Description: Iron dextran 1000 mg IV will be administered once, about 7 days prior to standard of care treatment.
Study: NCT05872854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericin
Description: HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible Light
Description: After application of HyBryte (0.25% hypericin ointment), participants will be placed in a light booth containing fluorescent light bulbs to activate the HyBryte.
Study: NCT06648668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMP-301
Description: Once daily \[QD\] × 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily \[QD\] × 14 days
Study: NCT06546592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI assisted contouring
Description: Initial are generated automatically using software powered by artificial intelligence
Study: NCT06545344

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palliative Care Consultation
Description: Attend a palliative care visit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tumor Board Review
Description: Undergo evaluation by tumor board

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor Board Review
Description: Undergo evaluation by tumor board
Study: NCT06214455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar diet and 10-12 hour eating window
Description: Low sugar diet and 10-12 hour eating window for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar diet and 10-12 hour eating window
Description: Low sugar diet and 10-12 hour eating window for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar diet, 8 hour eating window and fasting
Description: Low sugar diet, 8 hour eating window and a 36-60 hour fast once per week for four weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar diet, 8 hour eating window and fasting
Description: Low sugar diet, 8 hour eating window and a 36-60 hour fast once per week for four weeks.
Study: NCT06453811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-efficacy Theory-based Childbirth Preparation Program
Description: According to the block randomisation method, the couples who are included in the experimental group by applying the pre-test will be included in the programme in groups of 3-4 couples by planning the day and time they can participate in the programme. At the end of the sessions, the training guide reflecting the training content will be given to the couples and they will be asked to read it at home and do their homework by using the relevant parts of the guide. At the same time, these couples will continue their routine pregnancy controls in the hospital. It is planned to complete the trainings once a week, twice in total and for two weeks. After the trainings are completed, it is planned to send at least three reminders by text message until the calculated delivery date. Brochures and text message content related to the training content will be used in the reminder.
Study: NCT05745285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LLS Program
Description: The intervention will be conducted virtually. Participants will receive LLS's free patient and caregiver services including co-pay assistance, transportation and urgent need assistance, a scholarship program for young adult patients and survivors, one-on-one peer-to-peer support, online chats and support groups facilitated by clinical social workers, and nutrition counseling with a registered dietician for 6 months.
Study: NCT04889924

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Axillary Radiotherapy
Description: Axillary radiotherapy without lymphadenectomy (level I and II) + level III and supraclavicular +/- internal mammary chain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphadenectomy
Description: Axillary Lymph node dissection
Study: NCT05552755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-4881
Description: REC-4881 4mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-4881
Description: REC-4881 4mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-4881
Description: REC-4881 4mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-4881
Description: REC-4881 4mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT04760652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy CBT
Description: CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy CBT
Description: CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT
Study: NCT05979831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2325a
Description: Main Phase and Extension Phase: Loading IV dose followed by maintenance SC doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Main Phase: IV infusion followed by SC doses
Study: NCT05536895

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: C-Arm Cone Beam Computed Tomography
Description: C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Multi-detector Computed Tomography
Description: Conventional, standard of care perfusion imaging for AIS
Study: NCT06447506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: Participants will receive GSK1070806.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: Participants will receive GSK1070806.
Study: NCT05608512

Intervention type: OTHER
Intervention: interview
Description: The first phase included a qualitative study. We conducted a qualitative phenomenological method to better explicate and understand palliative care nurses' emotional labor experiences, as well as the dilemmas and solutions they encounter when physical, mental, and emotional labor intertwine at work. In the early stage, we compiled an interview outline by a written qualitative meta-analysis about the emotional labor, and added the contents in the interview outline according to the actual situation in the later interview process.
Study: NCT06126393

Intervention type: DIAGNOSTIC_TEST
Intervention: next generation sequencing AND Immunohistochemical examination
Description: First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.

Intervention type: DIAGNOSTIC_TEST
Intervention: next generation sequencing AND Immunohistochemical examination
Description: First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.

Intervention type: DIAGNOSTIC_TEST
Intervention: next generation sequencing AND Immunohistochemical examination
Description: First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.
Study: NCT04058457

Intervention type: DEVICE
Intervention: DBS
Description: Patients are tested pre-operatively and the post-operatively with their implanted neurostimulators ON and OFF. DBS implantation itself is part of routine care, and not part of the study.
Study: NCT05569369

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angioplasty and stenting
Description: dilatation of stenotic arteries and insertion of stent
Study: NCT05502952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Combined microneedling and topicalpentoxifylline vesrus intalesional pentoxifylline in Alopecia Areata patches in the same patient
Study: NCT06312397

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure
Description: For the acupressure group, a total of three points will be applied: the heart meridian 7th point (HT7), the large intestine meridian 4th point (LI4), and the stomach meridian 36th point (ST36), which is deemed appropriate in the lower extremity The symmetry of the three selected different points will also be applied to the other extremity.~After coronary angiography, acupressure will be applied for a total of 15 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham acupressure
Description: In the acupressure application applied to the sham group, parallel pressure will be applied to the bone area and points where the HT7, LI4, ST36 meridians do not pass.
Study: NCT06180434

Intervention type: RADIATION
Intervention: proton therapy
Description: Radiotherapy delivered with protons

Intervention type: RADIATION
Intervention: photon therapy
Description: Radiotherapy delivered with photons
Study: NCT06126393

Intervention type: DIAGNOSTIC_TEST
Intervention: next generation sequencing AND Immunohistochemical examination
Description: First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.
Study: NCT05586425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Skills + Treatment as Usual
Description: ERS has been updated to be friendlier to youth and involves learning skills for how to: (1) be more present in the moment, (2) effectively manage and respond to emotional experiences, (3) communicate your needs to others, and (4) increase your ability to tolerate distress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual entails psychiatric medication management, psychiatric management, individual support from peer mentors, drop-in activity groups, etc.
Study: NCT05919082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100
Description: Subjects will apply LEO 90100 topically; up to 15 g per day (or 105 g per week).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet® ointment
Description: Subjects will apply Daivobet® ointment topically; up to 15 g per day (or 105 g per week).
Study: NCT05886114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Multi-domain Intervention
Description: Structured Multi-domain Intervention (SMI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Guided Intervention
Description: In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
Study: NCT05819879

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peri capsular nerve group block
Description: The block will be administered under ultrasound guidance with low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease, at the level of anterior superior iliac spine. The scanning will be done with gradual caudad movement of the probe. After the anterior inferior iliac spine (AIIS) become visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of superior pubic ramus become visible. The psoas muscle with prominent tendon will be identified just above the pubic ramus. The target is the plane between these two structures. Aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a standard 25G Quincke needle will be introduced and 20 mL 0.125% bupivacaine with 4 mg dexamethasone was administered using ultrasound-guided out-of-plane technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaitico femoral block
Description: . After draping the left inguinal region, the femoral nerve will be identified lateral to the femoral artery using a 5- to 13-MHz linear phased array transducer ). Under ultrasound guidance, a 25G Quincke needle will be introduced toward the femoral nerve parallel to the ultrasound beam, and 20 mL of a local anesthetic mixture 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be injected. The trajectory of the needle was adjusted to achieve even distribution of the local anesthetics around the femoral nerve. Then, the patient will be placed in the right lateral position with the left hip and knee joints flexed by 30° to 50°. Following the identification of the left sciatic nerve located in the intermuscular plane of the gluteus maximus and medius muscles between the ipsilateral ischial tuberosity and greater trochanter using a convex phased array transducer 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be placed near the sciatic nerve through the 22-ga Tuohy needle
Study: NCT05359952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Starting the Conversation
Description: The Starting the Conversation intervention consists of a brief educational video and accompanying workbook with activities to help prepare patients to discuss sexual and menopausal types of health concerns effectively with gynecologic cancer providers, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback. In addition, participants receive a list of sexual and menopausal resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sexual and Menopausal Health Resources Only
Description: A list of resources on sexual/menopausal health both within and outside the institution, including websites.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual and Menopausal Health Resources Only
Description: A list of resources on sexual/menopausal health both within and outside the institution, including websites.